These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29738882)

  • 21. Differential effects of Cu
    Lorentzon E; Kumar R; Horvath I; Wittung-Stafshede P
    Biometals; 2020 Jun; 33(2-3):97-106. PubMed ID: 32170541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
    Oh Y
    BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers.
    Roberts RF; Bengoa-Vergniory N; Alegre-Abarrategui J
    Methods Mol Biol; 2019; 1948():69-76. PubMed ID: 30771171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions of α-synuclein oligomers with lipid membranes.
    Musteikytė G; Jayaram AK; Xu CK; Vendruscolo M; Krainer G; Knowles TPJ
    Biochim Biophys Acta Biomembr; 2021 Apr; 1863(4):183536. PubMed ID: 33373595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
    Sharma SK; Priya S
    Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of alpha-synuclein neurodegeneration.
    Waxman EA; Giasson BI
    Biochim Biophys Acta; 2009 Jul; 1792(7):616-24. PubMed ID: 18955133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural remodeling during amyloidogenesis of physiological Nα-acetylated α-synuclein.
    Gallea JI; Sarroukh R; Yunes-Quartino P; Ruysschaert JM; Raussens V; Celej MS
    Biochim Biophys Acta; 2016 May; 1864(5):501-10. PubMed ID: 26845568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein.
    Galvagnion C; Brown JW; Ouberai MM; Flagmeier P; Vendruscolo M; Buell AK; Sparr E; Dobson CM
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7065-70. PubMed ID: 27298346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heme Stabilization of α-Synuclein Oligomers during Amyloid Fibril Formation.
    Hayden EY; Kaur P; Williams TL; Matsui H; Yeh SR; Rousseau DL
    Biochemistry; 2015 Aug; 54(30):4599-610. PubMed ID: 26161848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biophysical studies of protein misfolding and aggregation in
    Sinnige T; Stroobants K; Dobson CM; Vendruscolo M
    Q Rev Biophys; 2020 Jun; 49():e22. PubMed ID: 32493529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disruptive membrane interactions of alpha-synuclein aggregates.
    Iyer A; Claessens MMAE
    Biochim Biophys Acta Proteins Proteom; 2019 May; 1867(5):468-482. PubMed ID: 30315896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders.
    Ugras S; Daniels MJ; Fazelinia H; Gould NS; Yocum AK; Luk KC; Luna E; Ding H; McKennan C; Seeholzer S; Martinez D; Evans P; Brown D; Duda JE; Ischiropoulos H
    EBioMedicine; 2018 May; 31():307-319. PubMed ID: 29759483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
    Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
    J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early stages of aggregation of engineered α-synuclein monomers and oligomers in solution.
    Li X; Dong C; Hoffmann M; Garen CR; Cortez LM; Petersen NO; Woodside MT
    Sci Rep; 2019 Feb; 9(1):1734. PubMed ID: 30741954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shedding light on aberrant interactions - a review of modern tools for studying protein aggregates.
    Kundel F; Tosatto L; Whiten DR; Wirthensohn DC; Horrocks MH; Klenerman D
    FEBS J; 2018 Oct; 285(19):3604-3630. PubMed ID: 29453901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
    Levine PM; Galesic A; Balana AT; Mahul-Mellier AL; Navarro MX; De Leon CA; Lashuel HA; Pratt MR
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1511-1519. PubMed ID: 30651314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.